Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Loss of function of the nuclear envelope protein LEMD2 causes DNA damage–dependent cardiomyopathy
Xurde M. Caravia, … , Ning Liu, Eric N. Olson
Xurde M. Caravia, … , Ning Liu, Eric N. Olson
Published November 15, 2022
Citation Information: J Clin Invest. 2022;132(22):e158897. https://doi.org/10.1172/JCI158897.
View: Text | PDF
Research Article Cardiology

Loss of function of the nuclear envelope protein LEMD2 causes DNA damage–dependent cardiomyopathy

  • Text
  • PDF
Abstract

Mutations in nuclear envelope proteins (NEPs) cause devastating genetic diseases, known as envelopathies, that primarily affect the heart and skeletal muscle. A mutation in the NEP LEM domain–containing protein 2 (LEMD2) causes severe cardiomyopathy in humans. However, the roles of LEMD2 in the heart and the pathological mechanisms responsible for its association with cardiac disease are unknown. We generated knockin (KI) mice carrying the human c.T38>G Lemd2 mutation, which causes a missense amino acid exchange (p.L13>R) in the LEM domain of the protein. These mice represent a preclinical model that phenocopies the human disease, as they developed severe dilated cardiomyopathy and cardiac fibrosis leading to premature death. At the cellular level, KI/KI cardiomyocytes exhibited disorganization of the transcriptionally silent heterochromatin associated with the nuclear envelope. Moreover, mice with cardiac-specific deletion of Lemd2 also died shortly after birth due to heart abnormalities. Cardiomyocytes lacking Lemd2 displayed nuclear envelope deformations and extensive DNA damage and apoptosis linked to p53 activation. Importantly, cardiomyocyte-specific Lemd2 gene therapy via adeno-associated virus rescued cardiac function in KI/KI mice. Together, our results reveal the essentiality of LEMD2 for genome stability and cardiac function and unveil its mechanistic association with human disease.

Authors

Xurde M. Caravia, Andres Ramirez-Martinez, Peiheng Gan, Feng Wang, John R. McAnally, Lin Xu, Rhonda Bassel-Duby, Ning Liu, Eric N. Olson

×

Figure 7

Lemd2 gene therapy improves cardiac function in KI/KI mice.

Options: View larger image (or click on image) Download as PowerPoint

Lemd2 gene therapy improves cardiac function in KI/KI mice.
(A) Schemat...
(A) Schematic of the AAV9-Lemd2 system for in vivo delivery. (B) Overview of the in vivo injection strategy. (C–G) Echocardiographic analysis of structural and functional parameters in hearts from 2-month-old WT (n = 7), KI/KI (n = 10), and KI/KI AAV9-Lemd2 mice (n = 4). The AAV9-Lemd2 treatment experiment was unblinded for mouse genotypes, and data are compared with untreated WT and KI/KI groups shown in Figure 2, A–F, that were not assessed contemporaneously. (C) Systolic LVAW thickness, (D) systolic LVID, (E) EF, (F) FS, and (G) LV volume. (H) H&E staining of 4-chamber view of 3-month-old hearts from WT, KI/KI, and KI/KI AAV9-Lemd2 mice. Scale bar: 500 μm. (I) Masson trichrome staining of 3-month-old hearts from WT, KI/KI, and KI/KI AAV9-Lemd2 mice. Scale bar: 50 μm. (J) Quantification of the percentage of cardiac fibrosis in hearts from WT, KI/KI, and KI/KI AAV9-Lemd2 mice. 4–5 cardiac sections per mouse. n = 1 mouse per genotype. **P < 0.01; *P < 0.05, 1-way ANOVA and Holm-Šidák test for correction of multiple comparisons. (K) Lemd2 mRNA expression in hearts from 2-month-old WT (n = 4), KI/KI (n = 4), and KI/KI AAV9-Lemd2 (n = 3) mice. ***P < 0.001, 1-way ANOVA and Holm-Šidák test for correction of multiple comparisons. (L) Western blot showing the levels of 2 cardiac LEMD2 protein isoforms in 2-month-old WT (n = 3), KI/KI (n = 3), and KI/KI AAV9-Lemd2 (n = 3) mice. Bottom: average and SEM of the relative LEMD2/GAPDH densitometry ratio in WT, KI/KI, and KI/KI AAV9-Lemd2 mice.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts